Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

Participants in this research study have stage I Non-Small Cell Lung Cancer (NSCLC) that was found to be suitable for surgery as a first line treatment. The usual treatment for this disease is to remove the tumor with surgery, and then evaluate after surgery if other additional treatments such as chemotherapy or targeted therapy are needed. The purpose of this research study is to compare three different ways of treating stage 1 NSCLC, to see if adding treatment before surgery can reduce the chance of the tumor recurring after surgical removal. In this study, patients will be randomly assigned to one of three treatments: * Durvalumab followed by surgical resection of the tumor. * Durvalumab plus ascorbate (also known as vitamin C), followed by surgical resection of the tumor. * Surgical resection alone. No therapy prior to surgery. This is the same as standard care (SOC) for this disease.